Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA.
BMJ. 2012 Oct 9;345:e6226. doi: 10.1136/bmj.e6226.
To determine the most effective tocolytic agent at delaying delivery.
Systematic review and network meta-analysis.
Cochrane Central Register of Controlled Trials, Medline, Medline In-Process, Embase, and CINAHL up to 17 February 2012.
Randomised controlled trials of tocolytic therapy in women at risk of preterm delivery.
At least two reviewers extracted data on study design, characteristics, number of participants, and outcomes reported (neonatal and maternal). A network meta-analysis was done using a random effects model with drug class effect. Two sensitivity analyses were carried out for the primary outcome; restricted to studies at low risk of bias and restricted to studies excluding women at high risk of preterm delivery (those with multiple gestation and ruptured membranes).
Of the 3263 titles initially identified, 95 randomized controlled trials of tocolytic therapy were reviewed. Compared with placebo, the probability of delivery being delayed by 48 hours was highest with prostaglandin inhibitors (odds ratio 5.39, 95% credible interval 2.14 to 12.34) followed by magnesium sulfate (2.76, 1.58 to 4.94), calcium channel blockers (2.71, 1.17 to 5.91), beta mimetics (2.41, 1.27 to 4.55), and the oxytocin receptor blocker atosiban (2.02, 1.10 to 3.80). No class of tocolytic was significantly superior to placebo in reducing neonatal respiratory distress syndrome. Compared with placebo, side effects requiring a change of medication were significantly higher for beta mimetics (22.68, 7.51 to 73.67), magnesium sulfate (8.15, 2.47 to 27.70), and calcium channel blockers (3.80, 1.02 to 16.92). Prostaglandin inhibitors and calcium channel blockers were the tocolytics with the best probability of being ranked in the top three medication classes for the outcomes of 48 hour delay in delivery, respiratory distress syndrome, neonatal mortality, and maternal side effects (all cause).
Prostaglandin inhibitors and calcium channel blockers had the highest probability of delaying delivery and improving neonatal and maternal outcomes.
确定最有效的保胎药物以延迟分娩。
系统评价和网络荟萃分析。
Cochrane 对照试验中心注册库、Medline、Medline 正在处理、Embase 和 CINAHL,检索日期为 2012 年 2 月 17 日。
有早产风险的孕妇接受保胎治疗的随机对照试验。
至少有 2 位评审员提取了研究设计、特征、参与者数量和报告结局(新生儿和产妇)的资料。采用随机效应模型进行药物类别效果的网络荟萃分析。对主要结局进行了 2 项敏感性分析;一项分析限定于低偏倚风险的研究,另一项分析限定于排除早产高风险(多胎妊娠和胎膜早破)的妇女的研究。
在最初确定的 3263 个标题中,有 95 项保胎治疗的随机对照试验被纳入综述。与安慰剂相比,前列腺素抑制剂使分娩时间延迟 48 小时的可能性最高(比值比 5.39,95%可信区间 2.14 至 12.34),其次是硫酸镁(2.76,1.58 至 4.94)、钙通道阻滞剂(2.71,1.17 至 5.91)、β拟交感神经药(2.41,1.27 至 4.55)和催产素受体拮抗剂阿托西班(2.02,1.10 至 3.80)。没有一类保胎药在降低新生儿呼吸窘迫综合征方面明显优于安慰剂。与安慰剂相比,β拟交感神经药(22.68,7.51 至 73.67)、硫酸镁(8.15,2.47 至 27.70)和钙通道阻滞剂(3.80,1.02 至 16.92)导致需要换药的副作用明显更高。前列腺素抑制剂和钙通道阻滞剂在分娩时间延迟 48 小时、呼吸窘迫综合征、新生儿死亡率和产妇副作用(所有原因)的结局中最有可能被排在前 3 位药物类别。
前列腺素抑制剂和钙通道阻滞剂最有可能延迟分娩并改善新生儿和产妇结局。